Use of portfolio analysis in data-driven decision making

George Santangelo, Ph.D.

Director, Office of Portfolio Analysis

DPCPSI/OD


National Institutes of Health

OFFICE OF PORTFOLIO ANALYSIS

STRATEGIC PLAN, FISCAL YEARS 2021-2025

OVERARCHING GOAL

To accelerate biomedical research by providing access to improved methods of data-driven decision making



Advancing Biomedical an

Developing, Maintaining, and Renewing Scientific Research Capac Exemplifying and Promoting the High Level of Scientific Integrity, Public Accountability, and Social Responsibi in the Conduct of Science The complete OPA strategic plan can be found on our website: https://dpcpsi.nih.gov/opa/strategicplan



Multifaceted approach to measuring productivity: IQRST



The IQRST Framework for evaluating productivity

- = Influence (weighted Relative Citation Ratio [RCR])
- $Q = \mathbf{Q}$ ualitative human judgment
- $R = \mathbf{R}igor/Reproducibility$ of research
- S = S haring of scientific data/resources
- T = **T**ranslation/Tech transfer (aggregated data on clinical trials, patents, drugs, and devices and/or <u>Approximate Potential</u> to <u>Translate score</u>)

Further detail on the value of using diverse, validated metrics to assess scientific output is described in a <u>peer-reviewed</u> <u>commentary</u> authored by the OPA Director in 2017. The *R* was previously discussed in this article as *Reproducibility* but has been updated to include the fundamental and, perhaps more important, principles of rigor and thorough reporting that underlie reproducibility.

Al/ML to detect and/or predict the impact of policy and funding decisions in real time OPA has successfully deployed Al/ML to measure scientific influence and predict clinical impact at the level of individual articles. OPA will continue to build on this momentum, developing new algorithms that harness the power of Al/ML to inform decision making. OPA Al/ML projects that are either planned or currently underway include the following:

- Support nimble decision making in response to public health crises and other emerging challenges (see <u>Figure 4</u>)
- Inform effective management of the training pipeline and scientific workforce OPA is also improving on strategies we began developing over the past few years to analyze trainee populations, training mechanisms, and workforce dynamics:
 - Study the distribution of expertise, career



RCR and APT scores are freely available in our public iCite tool

https://icite.od.nih.gov/





2016 Hutchins BI et al. PLoS Biology 14:e1002541 2017 Hutchins BI et al. PLoS Biology 15:e2003552 2019 Hutchins BI et al. PLOS Biology 17:e3000385 2019 Hutchins BI et al. PLoS Biology 17:e3000416










Citations

Roll over table headers for definitions; visit the Global RCR Stats page for percentile tables

Total Pubs	Pubs Per Year		Cites Per	Cites Per Year			Relative Citation Ratio (RCR)				Weighted RCR
		MAX	MEAN	SEM	MED	1	MAX	MEAN	SEM	MED	
793	52.87	143.50	7.01	0.36	4.43		51.08	2.55	0.13	1.64	1902.42







Customization

As you make changes below, the summary information and charts above are updated.

From 2008 V To 2022 V

☐ Only research articles

Only papers cited by clinical articles

Only clinical articles

Clear Filters

Total Pubs: 793 Export ▼

RCR and APT scores are freely available in our public iCite tool

https://icite.od.nih.gov/






2016 Hutchins BI et al. *PLoS Biology* 14:e1002541 2017 Hutchins BI et al. *PLoS Biology* 15:e2003552 2019 Hutchins BI et al. *PLOS Biology* 17:e3000385 2019 Hutchins BI et al. *PLoS Biology* 17:e3000416






Resul	ts Sign	
Influence	Translation Citations	

Total Pubs	Pubs Per Year	Avg. Human	Avg. Animal	Avg. Mol/Cell	Median RCR	Avg. APT	Cited By Clin.
793	52.87	0.17	0.43	0.40	1.64	26.4%	282





Click-drag around bubbles to lasso-select. Hit 'Esc' to deselect

Customization

From 2008 V To 2022 V

As you make changes below, the summary information and charts above are updated.

☐ Only research articles

☐ Only papers cited by clinical articles

☐ Only clinical articles

Clear Filters



Total Pubs: 793

RCR and APT scores are freely available in our public iCite tool

https://icite.od.nih.gov/





2016 Hutchins BI et al. PLoS Biology 14:e1002541 2017 Hutchins BI et al. PLoS Biology 15:e2003552 2019 Hutchins BI et al. PLOS Biology 17:e3000385 2019 Hutchins BI et al. PLoS Biology 17:e3000416






Results


Influence





Translation

Total Pubs	Pubs Per Year	Total Citations		Citations Per Pub			
			MAX	MEAN	SEM	MED	
793	52.87	45876	1722	57.85	3.71	31.00	









Clear Filters

Customization

As you make changes below, the summary information and charts above are updated.

From 2008 V To 2022 V

Only research articles

Only papers cited by clinical articles

Only clinical articles

Total Pubs: 793




A new public OPA tool coming soon to a browser near you!



watch for our limited beta launch in a few months! follow us on twitter for updates: MIH OPA

A new public OPA tool coming soon to a browser near you!



A new public OPA tool coming soon to a browser near you!



Serotonin regulates pancreatic beta cell mass during pregnancy.

Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose he 2011

2010


10.33

10.03

0.75

0.50

Page 1 of 8 >



Organic synthesis


Biomedical engineering Nanoparticles Drug delivery

5 does 20,00% NH-funded

Surface properties Polymers

Hypertension Diet/nutrition

Coordination and data sharing can help funders make better decisions



Coordination and data sharing helps funders make better decisions

2022 Government Accountability Office (GAO) Analysis

Biomedical Research:

Observations on DOD's Management of Congressionally Directed Medical Research Programs


GAO-22-105107

Published: Jan 31, 2022. Publicly Released: Jan 31, 2022.

"DOD coordinates with the National Institutes of Health (NIH) and the Department of Veterans Affairs (VA) by leveraging shared data to identify and mitigate project overlap."



Overlap between the BMGF and NIH portfolios (2009-2014)




Box size corresponds to number of awards

of awards is shown in boxes without a topic label




Synergy can result from overlapping investments by different funders

A topic-wide example from clinical research: NIH & BMGF point-of-care publications 2011-2015



Average percentile of Relative Citation Ratio (RCR) values




RCR of median NIH pub 1.0 percentile of median NIH pub 50%



Synergy can result from overlapping investments by different funders


An anecdotal example from fundamental research: Publications (2016 to 2022) of a well-funded molecular immunologist





Detecting synergies at scale requires data of the highest quality

An anecdotal example from fundamental research: Publications (2016 to 2022) of a well-funded molecular immunologist





Detecting synergies at scale requires data of the highest quality




21 publications (2016 to 2022)

Our AI/ML algorithm identifies over 200 unique authors who have published as Liang Zhou, only one of whom is this well-funded molecular immunologist




Register

Search







Linking publications to people: disambiguation




Figure 2 from Yu et al. The effect of mentee and mentor gender on scientific productivity of applicants for NIH training fellowships. bioRxiv 10.1101/2021.02.02.429450 (February 3, 2021)




OPA analysis of the effect of mentee and mentor gender on the scientific productivity of applicants for NIH fellowships

We analyzed the relationship between mentoring and productivity with a carefully designed analytical approach and high quality data:

- 18,600 pre- and post-doctoral fellowship applications
 - F30, F31 and F32, K01, K08, K23, K99 respectively
 - FY2011 through FY2017
- Separated into four mentee-mentor dyads: FF, FM, MF, and MM
- Mentees identify their mentor(s) in every application
- Since fellowships are salary only, productivity relies upon (and was therefore normalized to) the research funds available to the mentor
- Publications were linked to mentees with high quality disambiguation, and productivity was measured with a multi-faceted framework




The effect of mentee/mentor gender on mentee productivity



Years since first training application (both awarded and unawarded)



The effect of mentee/mentor gender on mentee productivity



(both awarded and unawarded)





New OPA analytics


- Detecting emerging areas of biomedical research and measuring how rapidly (or slowly) each topic is progressing
- Tracking the development of past transformative breakthroughs
- Predicting which topics will produce future transformative breakthroughs in the next 2 to 12 years

New OPA analytics

- Detecting emerging areas of biomedical research and measuring how rapidly (or slowly) each topic is progressing
- Tracking the development of past transformative breakthroughs
- Predicting which topics will produce future transformative breakthroughs in the next 2 to 12 years








New OPA analytics


- Detecting emerging areas of biomedical research and measuring how rapidly (or slowly) each topic is progressing
- Tracking the development of past transformative breakthroughs
- Predicting which topics will produce future transformative breakthroughs in the next 2 to 12 years


Emergence of mRNA vaccines: Progression of key publications

1 Cationic liposome-mediated RNA transfection RCR 8.19 Proc Natl Acad Sci 1989









Office of Portfolio Analysis





Emergence of mRNA vaccines: Flow of information

1 Cationic liposome-mediated RNA transfection RCR 8.19

Proc Natl Acad Sci 1989

 Characterization of a messenger RNA RCR 2.26 polynucleotide vaccine vector Cancer Res 1995

3 In vivo application of RNA leads to induction of RCR 3.12 specific cytotoxic T lymphocytes and antibodies Eur J Immunol 2000

4 Polarization of immunity induced by direct RCR 1.46 injection of naked sequence-stabilized mRNA vaccines Cell Mol Life Sci 2004

5 Suppression of RNA recognition by Toll-like RCR 12.70 receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 2005

6 Results of the first phase I/II clinical RCR 2.75 vaccination trial with direct injection of mRNA J Immunother 2008

7 Incorporation of pseudouridine into mRNA yields RCR 7.86 superior nonimmunogenic vector with increased translational capacity and biological stability Mol Ther 2008

8 Incorporation of pseudouridine into mRNA enhances RCR 3.45 translation by diminishing PKR activation Nucleic Acids Res 2010 9 Nucleoside modifications in RNA limit activation of RCR 2.43 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L Nucleic Acids Res 2011

10 Generating the optimal mRNA for therapy: HPLC RCR 5.75 purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA Nucleic Acids Res 2011

11 Protective efficacy of in vitro synthesized, specific RCR 6.60 mRNA vaccines against influenza A virus infection Nat Biotechnol 2012

12 Validation of the wild-type influenza A human challenge RCR 4.05 model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study Clin Infect Dis 2015


13 Optimization of Lipid Nanoparticle Formulations for RCR 7.44 mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs Nano Lett 2015

14 Expression kinetics of nucleoside-modified mRNA RCR 8.56 delivered in lipid nanoparticles to mice by various routes J Control Release 2015 15 Preclinical and Clinical Demonstration of RCR 12.92 Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses Mol Ther 2017


16 Safety and immunogenicity of a mRNA rabies vaccine RCR 7.50 in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial Lancet 2017

2016

Clinical trial or guideline =



Clinical impact



Tech impact

1

NIH National Institutes of Health

Summary

- Our existing *iCite* tool is a freely available source of data that fully supports multifaceted assessments of the return on investments in biomedical research
- We will release a limited beta version of our new analytical tool with the next few months
 - Transformative features include AI/ML-driven visualizations, high quality disambiguation, and full coverage of both PubMed and biomedically relevant preprints
 - Let us know if you'd like a live demo for your group, and/or early access as a beta tester!
- Effective analyses of research portfolios requires high quality data
- Synergy can result from overlapping investments by different funders
 - We're eager to collaborate and learn from each other
 - We work on an academic rather than a commercial model; all shared data is kept confidential and held solely within our team
- We can accelerate progress in improving human health by working together to detect emerging areas, measure the rate of scientific advancement, capture the development of past transformative breakthroughs, and predict which topics will produce future breakthroughs

